Q9004 HCPCS Level II code: Department of veterans affairs whole health partner services
Q9004 is the HCPCS code for “Department of veterans affairs whole health partner services” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q9004Department of veterans affairs whole health partner services
Short description: Va whole health partner serv
HCPCS · United States
Medicare details
The indicators CMS publishes with Q9004 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Value not established
- Type of service
- Consultation
- BETOS category
- Undefined codes
- Added
- Oct 1, 2021
Where Q9004 sits
- 1Q codesTemporary codes
- 2Active code Q9004Department of veterans affairs whole health partner services
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q9004 mean?
Q9004 is the HCPCS code for “Department of veterans affairs whole health partner services” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q9004?
CMS lists Q9004’s Medicare coverage as “Carrier judgment” and its pricing as “Value not established”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q9004
All Q codesQ5171Injection, denosumab-mobz (boncresa), biosimilar, 1 mgQ5172Injection, filgrastim-laha (filkri), biosimilar, 1 microgramQ5173Injection, denosumab-adet (ponlimsi), biosimilar, 1 mgQ9001Assessment by chaplain servicesQ9002Counseling, individual, by chaplain servicesQ9003Counseling, group, by chaplain servicesQ9950Injection, sulfur hexafluoride lipid microspheres, per mlQ9951Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per mlQ9953Injection, iron-based magnetic resonance contrast agent, per mlQ9954Oral magnetic resonance contrast agent, per 100 mlQ9955Injection, perflexane lipid microspheres, per mlQ9956Injection, octafluoropropane microspheres, per ml